Lymphoblastic lymphoma (LBL) is a fast-growing cancer that develops from immature white blood cells, called lymphoblasts, that multiply out of control and accumulate in lymph nodes and other tissues. It accounts for roughly 2% of all non-Hodgkin lymphomas and occurs most often in children, teenagers, and young adults. About 90% of cases arise from T cells, while the remaining 10% come from B cells.
How LBL Differs From Leukemia
Lymphoblastic lymphoma and acute lymphoblastic leukemia (ALL) are closely related diseases that involve the same type of abnormal cell. The distinction comes down to where those cells concentrate. In lymphoblastic lymphoma, the cancer primarily forms masses in lymph nodes, the chest, or other organs, with relatively few cancer cells in the bone marrow. If more than 25% of the bone marrow is replaced by cancer cells at diagnosis, the disease is classified as leukemia instead of lymphoma. Someone with LBL may have enlarged lymph nodes but no cancer cells visible in routine blood work, while someone with ALL typically has cancer cells circulating in the blood and heavily infiltrating the marrow.
Because the two diseases sit on the same spectrum, they are treated with similar chemotherapy regimens. The World Health Organization groups them together under the label “lymphoblastic leukemia/lymphoma” in its classification system, recognizing them as different presentations of the same underlying biology.
T-Cell vs. B-Cell Subtypes
The dominant form, T-cell lymphoblastic lymphoma (T-LBL), tends to appear in adolescents and young men. It has a strong tendency to develop large masses in the chest, specifically in the area behind the breastbone where the thymus gland sits. B-cell lymphoblastic lymphoma (B-LBL) is far less common and more often involves lymph nodes in the skin, bone, or soft tissue rather than the chest.
The subtype matters for prognosis. In one large pediatric analysis, children with B-LBL had a 100% long-term survival rate, while those with T-LBL had five-year survival rates between roughly 80% and 85%, depending on disease stage. Early-stage T-LBL carried a 100% survival rate in the same study, with most of the risk concentrated in advanced-stage disease.
Common Symptoms
The symptoms of LBL depend heavily on where the cancer grows. Swollen, painless lymph nodes in the neck, above the collarbones, or in the armpits are a typical first sign. Up to 70% of patients develop a mass in the chest (mediastinum), and this is particularly characteristic of the T-cell subtype. These chest masses are often large and sit in the front of the chest cavity, sometimes accompanied by fluid buildup around the lungs.
A large mediastinal mass can press on nearby structures and cause symptoms that bring people to the emergency room: swelling of the face, neck, or arms from compression of the major vein that drains blood from the upper body (superior vena cava syndrome), difficulty breathing from pressure on the airway, or fluid accumulation around the heart. These complications can escalate quickly, which is why LBL sometimes presents as a medical emergency before a formal diagnosis is made.
General symptoms that overlap with many cancers also occur: unexplained fevers, drenching night sweats, unintended weight loss, and persistent fatigue.
How It Is Diagnosed
Diagnosis starts with a biopsy of an enlarged lymph node or mass. Under the microscope, lymphoblastic lymphoma cells look like small to medium-sized immature cells with very little visible internal structure. Pathologists then run a panel of specialized stains on the tissue to identify specific proteins on the surface of the cancer cells. T-cell LBL cells carry a protein called CD3 inside the cell, which confirms their T-cell identity. A marker called TdT, found in immature lymphoid cells, is also typically present and helps distinguish LBL from other lymphomas made up of mature cells.
Imaging scans of the chest, abdomen, and pelvis map where the disease has spread. A bone marrow biopsy determines whether cancer cells have infiltrated the marrow and, critically, whether the count stays below the 25% threshold that separates lymphoma from leukemia. A spinal tap checks for cancer cells in the fluid surrounding the brain and spinal cord, since LBL can spread to the central nervous system.
Staging
LBL is staged using a system originally developed for childhood non-Hodgkin lymphomas. Stage I means a single tumor or lymph node group is involved, excluding the chest and abdomen. Stage II involves multiple lymph node areas on the same side of the diaphragm, or a tumor with nearby lymph node involvement. Stage III covers disease on both sides of the diaphragm, any primary chest mass, or extensive abdominal disease. Stage IV means the cancer has spread to the central nervous system or bone marrow. Most patients with T-LBL are diagnosed at stage III or IV because of how quickly the disease grows and how commonly it produces a large chest mass.
Treatment Approach
Treatment for lymphoblastic lymphoma follows the same general blueprint used for acute lymphoblastic leukemia: intensive, multi-phase chemotherapy lasting roughly two years. The first phase, induction, aims to eliminate as many cancer cells as possible and typically lasts four to six weeks. Consolidation follows, using different drug combinations to destroy remaining cancer cells that survived induction. A maintenance phase of lower-intensity chemotherapy continues for one to two years to prevent the cancer from returning.
Throughout treatment, patients also receive chemotherapy injected directly into the spinal fluid to prevent or treat cancer spread to the brain and spinal cord. Radiation therapy to the chest is sometimes used for patients with large mediastinal masses, though its role has diminished as chemotherapy regimens have improved.
This intensive approach has dramatically improved outcomes, particularly in children. Pediatric protocols have achieved five- and ten-year overall survival rates near 88% to 89% across all stages. Adults generally have lower cure rates than children, partly because they tolerate the intensive chemotherapy regimens less well and partly because of biological differences in the disease.
Genetic Factors That Influence Outcomes
The genetic profile of the cancer cells plays a significant role in determining how aggressive the disease is and how well it responds to treatment. In B-cell LBL, certain chromosomal patterns carry a favorable prognosis. Cells with extra copies of many chromosomes (high hyperdiploidy, meaning 51 to 67 chromosomes instead of the normal 46) tend to respond well to chemotherapy. A specific gene rearrangement called ETV6::RUNX1 is also associated with good outcomes.
Other genetic changes signal higher risk. Cells with fewer than 43 chromosomes (hypodiploidy) carry a poor prognosis. A translocation known as the Philadelphia chromosome, which creates an abnormal fusion protein, historically predicted very poor outcomes, though targeted therapies have improved results for this group. Amplification of a region on chromosome 21, found in about 2% of pediatric cases, also indicates higher risk but benefits from intensified treatment.
When the Cancer Returns
Relapsed or treatment-resistant LBL is significantly harder to treat than newly diagnosed disease. Standard salvage options include a different chemotherapy combination followed by a stem cell transplant from a donor, which offers the best chance at long-term remission for patients whose cancer has come back.
For B-cell disease specifically, CAR-T cell therapy has emerged as a powerful option. This treatment involves collecting a patient’s own immune cells, genetically engineering them in a laboratory to recognize and attack the cancer, and infusing them back into the patient. The first CAR-T product targeting a protein called CD19 was approved in 2017 for relapsed B-cell ALL. Newer approaches target a different protein, CD22, or combine both targets to reduce the chance that cancer cells escape detection. Maintaining long-term remission after CAR-T therapy remains a challenge, and some patients go on to receive a stem cell transplant afterward to consolidate their response.